Recent Updates
Recently added Catalysts
PTGX Positive Sentiment

2026 European Hematology Association (EHA) Meeting

Thursday, June 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses findings from the Phase 3 VERIFY study on Rusfertide, highlighting its maintained efficacy and safety in patients with low-risk or high-risk Polycythemia Vera (PV). Additionally, it explores the drug's impact on PV-related symptoms and cytoreductive therapy use. Long-term results from related studies also indicate positive outcomes for phlebotomy-dependent patients.
Price reaction · baseline $110 (2026-06-11T19:35:00.000Z) · hit during market hours · clean, no other PTGX news in the window
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rusfertide shows maintained benefits in patients with Polycythemia Vera.
  • The Phase 3 VERIFY study demonstrates efficacy and safety.
  • Positive impact on patient-reported outcomes related to PV symptoms.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+39%
120-day peak, hindsight
Typical move
3.6%
average across 3 past catalysts
Lead asset
PTG-300
Phase 2 · β-thalassemia

Full Press Release Details

Benefit of Rusfertide Maintained in Patients (Pts) With Low-Risk or High-Risk Polycythemia Vera (PV): Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study
García-Gutiérrez G, et al
Impact of Rusfertide on Polycythemia Vera (PV)-Related Symptoms and Patient-Reported Outcome-Related Items in the Randomized, Double-Blind Phase 3 VERIFY Study
Lucchesi, A, et al
Effect of Rusfertide on Cytoreductive Therapy Use in Patients with Phlebotomy Dependent Polycythemia Vera: Post Hoc Analysis from the Randomized Controlled Phase 3 VERIFY Study
Palandri, F, et al
Thromboembolic and Progression Events in Phlebotomy-Dependent Patients with Polycythemia Vera (PV): Long-Term Results From the Phase 2 REVIVE and THRIVE Open-Label Extension Rusfertide Studies
Pemmaraju, N, et al

Frequently Asked Questions

What is Rusfertide's role in Polycythemia Vera?

Rusfertide is shown to maintain benefits for patients with Polycythemia Vera.

What were the findings of the Phase 3 VERIFY study?

The VERIFY study demonstrated the efficacy and safety of Rusfertide in PV patients.

How does Rusfertide affect patient-reported outcomes?

Rusfertide positively impacts PV-related symptoms and patient-reported outcomes.

What long-term results were observed in related studies?

Long-term results from REVIVE and THRIVE studies indicate positive outcomes for patients.

ShareAdd on Google
Tags: PTGX Viatris Investor Conferences Healthcare Rusfertide Polycythemia Vera Phase 3 VERIFY EHA 2026 clinical trials
Last updated: Jun 11, 2026

Biotech snapshot

Cash runway
$849M liquidity · $0M/mo burn
Low dilution risk
Lead asset
PTG-300Phase 2
β-thalassemia →

Catalyst track record

+39%
best trade around PTGX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for PTGX.

See every catalyst's timing & PoA →